Spero Therapeutics
SPRO
50 hedge funds and large institutions have $16.1M invested in Spero Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
9% more funds holding
Funds holding: 46 → 50 (+4)
5.92% more ownership
Funds ownership: 22.84% → 28.76% (+5.9%)
2% less capital invested
Capital invested by funds: $16.5M → $16.1M (-$391K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$1.04M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$185K |
| 3 |
Renaissance Technologies
New York
|
+$156K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$109K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$628K |
| 2 |
AIC
AWM Investment Company
New York
|
-$447K |
| 3 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$116K |
| 4 |
Man Group
London,
United Kingdom
|
-$51.6K |
| 5 |
Millennium Management
New York
|
-$43.1K |
SPRO Hedge Fund Activity: Q4 2024 in Review
50 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2024, worth a combined $16.1M — down 2.4% from $16.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SPRO positions and 8 closed out — a net gain of 4 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Murchinson, opening a new position worth an estimated $1.04M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $628K sold.
- 50 institutional investors held Spero Therapeutics (SPRO) as of Q4 2024, up from 46 in Q3 2024.
- Funds reported $16.1M of Spero Therapeutics stock for Q4 2024, down 2.4% quarter-over-quarter.
- 12 funds opened new Spero Therapeutics positions in Q4 2024 and 8 closed out, a net change of +4 holders.
- The largest Spero Therapeutics buyer in Q4 2024 was Murchinson, an estimated $1.04M added.
- The largest Spero Therapeutics seller in Q4 2024 was Novo Holdings A/S, an estimated $628K sold.
Based on aggregated 13F filings for Q4 2024.